Abivax is a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases.
Abivax's mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Abivax was founded in 2013 under the leadership of Truffle Capital by Phillipe Pouletty. The company is headquartered in Paris, France. Abivax closely cooperates with the CNRS Collaborative Laboratory in Montpellier, France.
Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (obefazimod) as well as liver cancer (ABX196).
Abivax has developed a portfolio of drug candidates targeting various inflammatory diseases. Its most advanced drug candidate, obefazimod, is in clinical development for the treatment of UC. The Company also plans to advance the clinical development of obefazimod in Crohn's disease ("CD") and RA, subject to the availability of resources and funding.
Abivax’s most advanced compound, obefazimod, has completed Phase 2a and Phase 2b clinical induction trials, investigating its potent anti-inflammatory effect and its potential ability to treat ulcerative colitis (UC).
Abivax is backed by TCGX, Sofinnova Partners, Truffle Capital, Invus, Venrock Healthcare Capital Partners, Deerfield Management Company, Deep Track Capital, Samsara BioCapital, Santé Holding, Boxer Capital, Commodore Capital, Great Point Partners, and others. The company closed a €130M in secondary shares financing on Feb 22, 2023. This brings Abivax's total funding to €226.2M to date. In 2015, Abivax launched its initial public offering on the stock market Euronext.